Recent approaches in nanocarrier‐based therapies for neglected tropical diseases

Abstract

Neglected tropical diseases (NTDs) remain major public health problems in developing countries. Reducing the burden of NTDs requires sustained collaborative drug discovery efforts to achieve the goals of the new NTDs roadmap launched by the World Health Organization. Oral drugs are the most convenient choice and usually the safest and least expensive. However, the oral use of some drugs for NTDs treatment has many drawbacks, including toxicity, adverse reactions, drug resistance, drug low solubility, and bioavailability. Since there is an imperative need for novel and more effective drugs to treat the various NTDs, in recent years, several compound‐loaded nanoparticles have been prepared with the objective of evaluating their application as an oral drug delivery system for the treatment of NTDs. This review focuses on the various types of nanoparticle drug delivery systems that have been recently used against the major NTDs caused by parasites such as leishmaniasis, Chagas disease, and schistosomiasis. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease

Nucleotides Entrapped in Liposome Nanovesicles as Tools for Therapeutic and Diagnostic Use in Biomedical Applications

“…Neglected diseases or neglected tropical diseases (NTDs) constitute a group of 20 conditions, including dengue, chikungunya, trypanosomiasis, and leishmaniasis. These diseases primarily affect impoverished communities and disproportionately affect women and children, culminating in devastating health, social and economic consequences for billions of people [ 123 , 124 ].…”

The Existing Drug Nifuroxazide as an Antischistosomal Agent: In Vitro , In Vivo , and In Silico Studies of Macromolecular Targets

“…However, any possibility of selection of the parasites for praziquantel resistance or low sensitivity may hamper the 2030 target of global disease elimination. As a result, the WHO recognizes the importance of initiatives for the development of safe, affordable, and effective drugs for schistosomiasis ( 9 – 11 ).…”

Evaluating the Antischistosomal Activity of Dehydrodieugenol B and Its Methyl Ether Isolated from Nectandra leucantha─A Preclinical Study against Schistosoma mansoni Infection

“…7 Consequently, there is an urgent call for the development of innovative anthelmintic agents to address this pressing global health issue. 6,8 Natural products have long been recognized as valuable sources of substances with pharmacological properties, and among them, various metabolites with antischistosomal properties have been identified. Notably, neolignans are one such example.…”

“…Moreover, due to the neglect associated with this disease, there is limited pharmaceutical investment in exploring novel antischistosomal agents. , As a result, schistosomiasis has been targeted for elimination by 2030 in the World Health Organization’s (WHO) neglected tropical diseases (NTDs) roadmap . Consequently, there is an urgent call for the development of innovative anthelmintic agents to address this pressing global health issue. , …”

“…7 Consequently, there is an urgent call for the development of innovative anthelmintic agents to address this pressing global health issue. 6 , 8 …”